Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTBNASDAQ:ITRMNASDAQ:MURANASDAQ:PRTG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$0.81$0.76$0.51▼$2.08$44.83M-0.2256,450 shs40,783 shsITRMIterum Therapeutics$1.06-15.9%$1.27$0.81▼$3.02$36.66M2.87990,028 shs1.14 million shsMURAMural Oncology$2.62+0.4%$2.64$0.95▼$4.74$45.14M5.281.30 million shs401,832 shsPRTGPortage Biotech$11.03+2.4%$5.98$2.10▼$23.01$11.57M0.54975,080 shs348,568 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma+3.71%+8.72%+19.12%-17.35%-39.55%ITRMIterum Therapeutics0.00%+22.33%0.00%-15.44%-24.55%MURAMural Oncology+0.38%-2.97%+121.19%-31.85%-27.09%PRTGPortage Biotech+27.46%+18.48%+12.19%+129.15%+124.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTBConnect Biopharma2.6108 of 5 stars3.53.00.00.01.82.50.6ITRMIterum Therapeutics2.6046 of 5 stars3.55.00.00.03.60.00.0MURAMural Oncology3.0759 of 5 stars3.35.00.00.01.71.71.3PRTGPortage Biotech0.9058 of 5 stars0.04.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 3.00Buy$8.00887.65% UpsideITRMIterum Therapeutics 3.00Buy$5.00371.70% UpsideMURAMural Oncology 2.60Moderate Buy$13.00396.18% UpsidePRTGPortage Biotech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRTG, MURA, CNTB, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/12/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$24.12M1.86N/AN/A$1.83 per share0.44ITRMIterum TherapeuticsN/AN/AN/AN/A($0.12) per shareN/AMURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/APRTGPortage BiotechN/AN/A$19.02 per share0.58$3.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$59.50MN/A0.00N/AN/AN/AN/AN/AN/AITRMIterum Therapeutics-$24.77M-$1.31N/A∞N/AN/AN/A-90.85%5/12/2025 (Estimated)MURAMural Oncology-$207.45M-$7.58N/AN/AN/AN/A-70.10%-61.30%5/13/2025 (Estimated)PRTGPortage Biotech-$75.34M-$41.65N/A∞N/AN/A-342.34%-196.47%4/29/2025 (Estimated)Latest PRTG, MURA, CNTB, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/AMURAMural Oncology-$1.68N/AN/AN/AN/AN/A5/12/2025Q1 2025ITRMIterum Therapeutics-$0.23N/AN/AN/AN/AN/A3/11/2025Q4MURAMural Oncology-$1.96-$2.01-$0.05-$2.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect BiopharmaN/A12.04N/AITRMIterum TherapeuticsN/A1.411.41MURAMural OncologyN/A7.387.38PRTGPortage BiotechN/A3.083.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%ITRMIterum Therapeutics9.21%MURAMural Oncology80.21%PRTGPortage Biotech13.36%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%ITRMIterum Therapeutics9.20%MURAMural Oncology0.06%PRTGPortage Biotech42.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11055.35 million42.77 millionOptionableITRMIterum Therapeutics1034.58 million31.40 millionNot OptionableMURAMural Oncology11917.23 million17.01 millionOptionablePRTGPortage Biotech61.05 million608,000OptionablePRTG, MURA, CNTB, and ITRM HeadlinesRecent News About These CompaniesPortage Biotech Shares Rise on Confirmatory Trial Results, Plans for Human TrialApril 28 at 11:56 PM | marketwatch.comPortage Biotech stock soars on promising preclinical resultsApril 28 at 11:56 PM | za.investing.comPortage Biotech Stock Surges On New Preclinical Data In Mesothelioma Trial: Retail Gets More BullishApril 28 at 11:56 PM | msn.comPortage Biotech Inc. Reports Positive Preclinical Efficacy Data for PORT-7 at AACR Annual Meeting 2025April 28 at 6:22 AM | quiverquant.comPortage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7April 28 at 6:00 AM | globenewswire.comInsider Stock Buying Reaches US$2.15m On Portage BiotechApril 26 at 10:58 AM | finance.yahoo.comPortage Biotech Inc. Common Stock (PRTG) Pre-MarketMarch 30, 2025 | nasdaq.comPortage Biotech presents preclinical data for PORT-7March 28, 2025 | markets.businessinsider.comPortage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment TrialMarch 27, 2025 | marketwatch.comPortage Biotech stock soars on promising preclinical dataMarch 27, 2025 | investing.comPortage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7March 27, 2025 | markets.businessinsider.comPortage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6March 14, 2025 | nasdaq.comPortage Biotech Inc. Announces New Director Compensation Plan and Stock Option GrantsMarch 13, 2025 | tipranks.comPortage resumes enrollment in final cohort of dose escalation for ADPORT-601March 12, 2025 | markets.businessinsider.comPortage Biotech Resumes Key Trial Enrollment, Advances Innovative Immunotherapy ApproachMarch 12, 2025 | tipranks.comPortage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 TrialMarch 12, 2025 | globenewswire.comPortage Biotech Inc.: Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing RequirementsFebruary 19, 2025 | finanznachrichten.dePortage Biotech Granted Nasdaq Compliance ExtensionFebruary 12, 2025 | tipranks.comPortage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing RequirementsFebruary 12, 2025 | globenewswire.comPortage Biotech Announces Completion of $2.15 Million Private FinancingJanuary 30, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTG, MURA, CNTB, and ITRM Company DescriptionsConnect Biopharma NASDAQ:CNTB$0.81 0.00 (0.00%) Closing price 03:56 PM EasternExtended Trading$0.81 0.00 (0.00%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Iterum Therapeutics NASDAQ:ITRM$1.06 -0.20 (-15.87%) Closing price 04:00 PM EasternExtended Trading$1.04 -0.02 (-1.42%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Mural Oncology NASDAQ:MURA$2.62 +0.01 (+0.38%) Closing price 04:00 PM EasternExtended Trading$2.60 -0.02 (-0.95%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Portage Biotech NASDAQ:PRTG$11.03 +0.26 (+2.41%) Closing price 04:00 PM EasternExtended Trading$10.80 -0.23 (-2.04%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
